about
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.New information on the genetics of stroke.Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?Stroke Genetics Update: 2011A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients.Species Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel.Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.TRITON and beyond: new insights into the profile of prasugrel.Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.Unstable angina and non-ST elevation myocardial infarction.Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.Prasugrel is effective and safe for neurointerventional procedures.Facilitated/pharmaco-invasive approaches in STEMI.Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.Recent advances in antithrombotic treatment for acute coronary syndromes.Prasugrel hydrochloride for the treatment of acute coronary syndromes.Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention.Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Platelet function testing in cardiac surgery.Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel.Iatrogenic bleeding during flexible bronchoscopy: risk factors, prophylactic measures and management.Prophylactic Antiplatelet Medication in Endovascular Treatment of Intracranial Aneurysms: Low-Dose Prasugrel versus Clopidogrel.P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?Immediate and Long-Term Therapy of Patients with Acute Coronary Syndromes with Thienopyridines. Current Status According to the Latest European Society of Cardiology (ESC) Guidelines.Clinical outcomes, resource use, and costs at 1 year in patients with acute coronary syndrome undergoing PCI: results from the multinational APTOR registry.Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel.ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome
P2860
Q34536091-F478FFD1-CB68-4469-BE5F-62FB8284FB5BQ34664010-2ABE0073-2570-47A1-AEA6-955FFDF713E4Q35035904-7988405C-2B21-4F73-98E1-DC33132C5779Q35602462-439B3BE5-7CD9-4F91-AE0B-962C2B1B53FAQ36363183-396457E8-0D3F-45BE-87D1-EAC0203EC9B1Q37319541-B2956831-3CFC-4861-8C98-7A9CA1172E05Q37818331-53241517-AF9E-4B08-B7C0-F583B82C43A5Q37925009-BAAA9AB4-B68E-4889-8ED0-612F23785CFFQ37943829-0EF396D9-AAC3-4379-A6FC-6D27495A553EQ37972109-1E229D3E-4214-4E11-A730-51662D656346Q37982427-2D0E7022-1E66-42B9-BC2A-A9534742CC93Q38012439-30807936-1A99-4FED-816E-896756CFCBD3Q38037668-0E114899-A21A-40F4-9FB1-CDEEADBEE95FQ38065738-97B28C74-DA18-423E-B5D2-114BABC856C9Q38132252-EAA709BE-442A-48AC-9194-945CFFE54E55Q38216600-5B15E65A-46E3-4BED-96A4-E0A80AD65911Q38336838-D669498F-344E-4318-828C-62D440163723Q38340126-86946713-7F49-42C9-B8D4-B61CE2366784Q38557198-DE589EE0-DF9B-4828-9E3E-005F0F5CCAB1Q38750444-CB8C9CB8-EC98-460E-8010-FC88CE90F12BQ38930441-A458AF45-6FF2-43BB-B4D9-E6D6F819C3B7Q39350090-1DA8213C-C432-43B2-8E06-BCA468954906Q39401582-92DD7217-96AB-4B4C-98DC-DC0756017B1BQ39622468-1AB3E6B0-0D0E-4D2C-9C5D-F062BB68CF5CQ41511099-6D35CA44-A3E8-4BC0-B5E2-62F6A0BA084CQ42093931-9622F99E-5155-45DB-ADE1-6F3A3330B651Q44136454-8B623F8E-D3B8-4BB9-84EA-36B5FC141184Q48246774-CF44BB5A-16C8-4C10-837C-4DFAC60E3492Q51017538-D73D9948-8E48-413F-B5D6-8B246FBC50CEQ57764209-5AA2735F-E13B-4E69-BAED-CF66B1773FD8
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prasugrel.
@en
Prasugrel.
@nl
type
label
Prasugrel.
@en
Prasugrel.
@nl
prefLabel
Prasugrel.
@en
Prasugrel.
@nl
P1433
P1476
Prasugrel.
@en
P2093
Stephen D Wiviott
P304
P356
10.1161/CIRCULATIONAHA.109.921502
P407
P577
2010-07-01T00:00:00Z